sevelamer

(redirected from Sevelamer hydrochloride)
Also found in: Dictionary.

sevelamer

 [sĕ-vel´ah-mer]
a phosphate binder used as the hydrochloride salt to reduce serum phosphorus concentrations in hyperphosphatemia associated with end-stage renal disease; administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

sevelamer

A phosphate chelator used to reduce phosphorus in patients with end-stage renal disease and in chronic renal failure patients not requiring dialysis. It also reduces uric acid levels, and may be of use in patients with hyperuricaemia, uric acid nephrolithiasis and gout.

Adverse effects
Blood pressure lability (hypo- or hypertension), nausea, vomiting, dyspepsia, diarrhoea, constipation.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

sevelamer

Renagel® Nephrology A chelator used to ↓ phosphorus in Pts with ESRD and in chronic renal failure Pts not requiring dialysis. See Chelation, End-stage renal disease.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Sevelamer hydrochloride is a non-absorbable polymer that contains neither aluminum, lanthanum, or calcium.
Sevelamer carbonate (Renvela[R]) is a similar compound, and is derived from sevelamer hydrochloride. It exists as a buffered form of the original drug, and studies suggest that it may be better tolerated than sevelamer hydrochloride, although this finding is not consistent (Cozzolino et al., 2012).
The criteria for coverage are similar to that of sevelamer hydrochloride (Renagel[R]).
An in vitro study investigated the ET binding affinity of sevelamer hydrochloride using 10 ng/mL of E.
Jaber, "Endotoxin-binding affinity of sevelamer hydrochloride," The American Journal of Nephrology, vol.
A randomized crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis.
Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels.
Two polymer products have been brought to market, Renagel(R) (sevelamer hydrochloride), a calcium-free, metal-free phosphate binder for patients with end-stage renal disease, and WelChol(R) (colesevelum hydrocholoride), a cholesterol-lowering agent.
Genzyme's primary drug in the kidney transplant area is Renagel (sevelamer hydrochloride), a phosphate binder for patients with end stage renal disease undergoing hemodialysis.